Cingulate Secures Key Patent for Precision‑Timed ADHD Drug, Boosting Market Edge
Read how Cingulate Inc.’s new U.S. patent for its Precision‑Timed Release ADHD therapy CTx‑1301 could reshape treatment and market strategy.
3 minutes to read
CINGULATE INC
How Cingulate Inc.’s Board Restructuring Could Accelerate Pharma Innovation
Explore how Cingulate Inc.’s board shrinkage and new chairman reshape its strategy, boosting efficiency and accelerating drug development for patients.
3 minutes to read
Cingulate Inc. Struggles Amid Nasdaq Volatility Amidst Biopharmaceutical Challenges
Cingulate Inc., a clinical-stage biopharmaceutical company, faces significant financial and operational challenges as it navigates the complex landscape of the healthcare sector.
2 minutes to read